86
Treatment
Phase II
Taper GC
Target
achieved?
Consult
expert center
Consider tocilizumab
or
TNF-inhibitor
Taper
tocilizumab or
TNF-inhibitor
YES
NO
Continue
taper
Start GC
40–60 mg/d
Taper GC to 1–20
mg/d within 2–3
mo and then to ≤10
mg/d after 1 y
Phase I
YES
Figure 26. The 2018 European Alliance of Associations for
Rheumatology (EULAR; Formerly European League
Against Rheumatism) Recommended Algorithm for
the Pharmacological Treatment of Takayasu Arteritis
+
Diagnosis of Active
Takayasu Arteritis
Target achieved?
Start csDMARD
